Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZK-805623
- Development stage
- Preclinical
- Lead developer
- Bayer HealthCare Pharmaceuticals
- Modality
- Small Molecules
01
Overview
ZK-805623 is an experimental small molecule compound classified as a diarylether derivative. It was developed by Bayer HealthCare Pharmaceuticals as a potent, selective inhibitor of factor Xa, a key serine protease in the coagulation cascade. By inhibiting factor Xa, ZK-805623 was investigated for its potential antithrombotic effects and possible use in the prevention or treatment of thrombosis and related cardiovascular diseases. The compound is structurally related to other diphenoxypyridine derivatives and has been studied in preclinical settings but did not advance to clinical development[1][2][3]. No approved indications or marketed formulations exist for this drug.
02
Targets
F10 (Factor Xa)
Beyond the preview
Go deeper on ZK-805623.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZK-805623.